Half Year 2020 Oxford BioMedica PLC Earnings Call Transcript
Good afternoon, ladies and gentlemen, and welcome to Oxford Biomedica's Interim Results Conference Call. We are delighted today to talk through what hopefully you agree is a strong set of results for the 6 months ended the 30th of June, on a backdrop of what for all of us has been unprecedented times.
As you'll see, Oxford Biomedica has never been busier, not only in our core area of lenti-based cell and gene therapy, but also in the fight against COVID through our work on AstraZeneca's vaccine. On the call with me today is our CEO, John Dawson; and CFO, Stuart Paynter. (Operator Instructions) And the presentation is being recorded. (Operator Instructions)
With that, I'd like to hand over to John Dawson.
Thank you, Catherine, and we're showing you currently the forward-looking statement slide. And during the presentation, we'll make forward-looking statements which cannot be relied upon.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |